To explore a potential treatment strategy for HCC, we tested the apoptosis-inducing effect of sorafenib (the first drug approved for advanced HCC treatment) in combination with auranofin (an inhibitor of thioredoxin reductase) in vitro. The gene discussed is PRDX5; the disease is hepatocellular carcinoma.